Literature DB >> 33347088

Mind the Gap: Current Treatment Alternatives for GERD Patients Failing Medical Treatment and Not Ready for a Fundoplication.

Phuong Huynh1,2, Vani Konda3, Suchakree Sanguansataya4, Marc A Ward1,2,4, Steven G Leeds1,2,4.   

Abstract

BACKGROUND: Gastroesophageal reflux disease is associated with Barrett esophagus, esophageal adenocarcinoma, and significantly impacts quality of life. Medical management is the first line therapy with surgical fundoplication as an alternative therapy. However, a small portion of patients who fail medical therapy are referred for surgical consultation. This creates a "gap" in therapy for those patients dissatisfied with medical therapy but are not getting referred for surgical consultation. Three procedures have been designed to address these patients. These include radiofrequency ablation (RFA) of the lower esophageal sphincter, transoral incisionless fundoplication (TIF), and magnetic sphincter augmentation.
MATERIALS AND METHODS: A Pubmed literature review was conducted of all publications for RFA, TIF, and MSA. Four most common endpoints for the 3 procedures were compared at different intervals of follow-up. These include percent of patients off proton pump inhibitors (PPIs), GERD-HRQL score, DeMeester score, and percent of time with pH <4. A second query was performed for patients treated with PPI and fundoplications to match the same 4 endpoints as a control.
RESULTS: Variable freedom from PPI was reported at 1 year for RFA with a weighted mean of 62%, TIF with a weighted mean of 61%, MSA with a weighted mean of 85%, and fundoplications with a weighted mean of 84%. All procedures including PPIs improved quality-of-life scores but were not equal. Fundoplication had the best improvement followed by MSA, TIF, RFA, and PPI, respectively. DeMeester scores are variable after all procedures and PPIs. All MSA studies showed normalization of pH, whereas only 4 of 17 RFA studies and 3 of 11 TIF studies reported normalization of pH.
CONCLUSIONS: Our literature review compares 3 rival procedures to treat "gap" patients for gastroesophageal reflux disease with 4 common endpoints. Magnetic sphincter augmentation appears to have the most reproducible and linear outcomes but is the most invasive of the 3 procedures. MSA outcomes most closely mirrors that of fundoplication.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 33347088      PMCID: PMC8154178          DOI: 10.1097/SLE.0000000000000888

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  126 in total

1.  Outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease in non-responders to proton pump inhibitors.

Authors:  Emad Hamdy; Ayman El Nakeeb; Hosam Hamed; Mohamed El Hemaly; Nabil Gad ElHak
Journal:  J Gastrointest Surg       Date:  2014-07-02       Impact factor: 3.452

2.  Five-year follow-up of a prospective study comparing laparoscopic Nissen fundoplication with Stretta radiofrequency for gastroesophageal reflux disease.

Authors:  W T Liang; J N Wu; F Wang; Z W Hu; Z G Wang; T Ji; X L Zhan; C Zhang
Journal:  Minerva Chir       Date:  2014-08       Impact factor: 1.000

3.  Magnetic sphincter augmentation: a viable rescue therapy for symptomatic reflux following bariatric surgery.

Authors:  Ryan C Broderick; C Daniel Smith; Joslin N Cheverie; Pablo Omelanczuk; Arielle M Lee; Rebeca Dominguez-Profeta; Robert Cubas; Garth R Jacobsen; Bryan J Sandler; Karl-Hermann Fuchs; Santiago Horgan
Journal:  Surg Endosc       Date:  2019-09-04       Impact factor: 4.584

4.  Randomised clinical trial: transoral incisionless fundoplication vs. sham intervention to control chronic GERD.

Authors:  B Håkansson; M Montgomery; G B Cadiere; A Rajan; S Bruley des Varannes; M Lerhun; E Coron; J Tack; R Bischops; A Thorell; U Arnelo; L Lundell
Journal:  Aliment Pharmacol Ther       Date:  2015-10-13       Impact factor: 8.171

5.  Three year's experience with the Stretta procedure: did it really make a difference?

Authors:  R E Lutfi; A Torquati; J Kaiser; M Holzman; W O Richards
Journal:  Surg Endosc       Date:  2004-12-23       Impact factor: 4.584

6.  Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial.

Authors:  Douglas A Corley; Philip Katz; John M Wo; Andreas Stefan; Marco Patti; Richard Rothstein; Steven Edmundowicz; Michael Kline; Rodney Mason; M Michael Wolfe
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

7.  LINX(®) Reflux Management System in chronic gastroesophageal reflux: a novel effective technology for restoring the natural barrier to reflux.

Authors:  Luigi Bonavina; Greta Saino; John C Lipham; Tom R Demeester
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

8.  Durability of Stretta Radiofrequency Treatment for GERD: Results of an 8-Year Follow-Up.

Authors:  Luca Dughera; Gianluca Rotondano; Maria De Cento; Paola Cassolino; Fabio Cisarò
Journal:  Gastroenterol Res Pract       Date:  2014-05-18       Impact factor: 2.260

9.  Diagnosis and Anti-Reflux Therapy for GERD with Respiratory Symptoms: A Study Using Multichannel Intraluminal Impedance-pH Monitoring.

Authors:  Chao Zhang; Jimin Wu; Zhiwei Hu; Chao Yan; Xiang Gao; Weitao Liang; Diangang Liu; Fei Li; Zhonggao Wang
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

10.  Long-term outcomes of patients with refractory gastroesophageal reflux disease following a minimally invasive endoscopic procedure: a prospective observational study.

Authors:  Wei-Tao Liang; Zhong-Gao Wang; Feng Wang; Yue Yang; Zhi-Wei Hu; Jian-Jun Liu; Guang-Chang Zhu; Chao Zhang; Ji-Min Wu
Journal:  BMC Gastroenterol       Date:  2014-10-10       Impact factor: 3.067

View more
  1 in total

1.  Efficacy of Endoscopic Radiofrequency Ablation for Treatment of Reflux Hypersensitivity: A Study Based on Rome IV Criteria.

Authors:  Yuan-Xi Jiang; Zhi-Yu Dong; Jun-Wen Wang; Ying Chen; Hui-Hui Sun; Shu-Chang Xu
Journal:  Gastroenterol Res Pract       Date:  2022-03-27       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.